Cytopoint now approved to treat canine allergic dermatitisSeptember 17, 2018Zoetis announced the U.S. Department of Agriculture (USDA) has granted an expanded indication for Cytopoint, a monoclonal antibody (mAb) therapy for the treatment of allergic dermatitis in dogs. Administered every four to eight weeks, one injection of Cytopoint works by targeting and neutralizing interleukin-31 (IL-31), a key protein involved in triggering itch in dogs, offering both convenience and sustained efficacy, according to Zoetis. "This approval gives veterinarians much-needed flexibility for personalized treatment of allergic and atopic dermatitis in dogs with two therapeutic approaches—the injectable Cytopoint and the oral tablet Apoquel," said Thomas P. Lewis II, DVM, DACVD, of Dermatology for Animals in Gilbert, Ariz. "Allergic dogs and their owners have a variety of needs, and these medications from Zoetis can bring fast and long-lasting relief to my canine allergy patients, as well as bring peace of mind to their owners." Apoquel (oclacitinib tablet) is formulated to start relieving itch within four hours and provides veterinarians with the flexibility to start and stop itch control, according to Zoetis. Cytopoint begins to relieve itch within 24 hours and provides sustained itch relief for four to eight weeks, giving the skin time to heal, the company stated. They may …
SPONSORED CONTENTThe Case for Year-Round Heartworm Prevention and Affordable OptionsVeterinarians are often more than just clinicians - they’re advisors, educators, and, increasingly, financial counselors. In today’s economy, pet owners may hesitate to invest in year-round prevention due to budget constraints; but, skipping even a few months of heartworm protection can have serious consequences. + Learn More
Soothe the itchMay 1, 2018Whether it’s from allergies, bacterial infections, or external parasites such as fleas or mites, pruritus is easily among the top 10 problems veterinarians see in dogs and cats. Atopic disease alone is the No. 1 most common condition in dogs and the eighth most common in cats.
What Veterinary Practice News readers loved in 2017December 15, 2017Another new year is upon us, but before we embrace 2018 and all it might have to offer veterinary professionals and the industry, let's recap Veterinary Practice News' 10 most-read features of 2017. 1. Canine influenza virus 2017: Beyond two show dogs 2. 10 secrets to keep your veterinary nurses happy 3. University of Minnesota develops cancer drug that helps dogs with hemangiosarcoma 4. Study: Cats eating dry food have increased risk for developing Type 2 diabetes 5. Zoetis earns license for Cytopoint skin therapy 6. Raising greyhound health awareness 7. American Association of Feline Practitioners revises declawing position 8. The 7 top challenges facing veterinary medicine in 2017 9. Petco officially enters the veterinary hospital ring with Thrive 10. The strangest things vet techs have heard clients say
Zoetis earns license for Cytopoint skin therapyJanuary 4, 2017Veterinary drug maker Zoetis Inc. in December received a U.S. Department of Agriculture license for Cytopoint, which the Parsippany, N.J., company described as the first monoclonal antibody (mAb) therapy approved “to help provide sustained control of the clinical signs associated with atopic dermatitis in dogs.”
